Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1 2027 Novel Switch-II scaffold and pseudo-irreversible binding designed to enable prolonged, potent and selective inhibition of mutant KRAS to potentially achieve improved efficacy and tolerability SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clin ...